Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2742 |
| _version_ | 1797842073611665408 |
|---|---|
| author | L. V. Bolotina A. D. Kaprin |
| author_facet | L. V. Bolotina A. D. Kaprin |
| author_sort | L. V. Bolotina |
| collection | DOAJ |
| description | The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but also the option of the previous line therapy, its effectiveness and toxicity. Treatment with anti-EGFR antibodies (AT) did not significant improve overall survival (OS) in comparison with chemotherapy in the secondline regimens, in contrast to antiangiogenic drugs. Among this group of MAT, aflibercept provides the best results in a selected group of patients (the highly effective group) and a controlled toxicity profile. |
| first_indexed | 2024-04-09T16:41:49Z |
| format | Article |
| id | doaj.art-f2e577b03a7b446dba9131e42e9812f5 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:41:49Z |
| publishDate | 2018-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-f2e577b03a7b446dba9131e42e9812f52023-04-23T06:56:40ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-11-01019222610.21518/2079-701X-2018-19-22-262684Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choicesL. V. Bolotina0A. D. Kaprin1Gertsen Moscow Research Oncological Institute, Branch of National Medical Research Radiological Center of the Ministry of Health of the Russian FederationGertsen Moscow Research Oncological Institute, Branch of National Medical Research Radiological Center of the Ministry of Health of the Russian FederationThe most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but also the option of the previous line therapy, its effectiveness and toxicity. Treatment with anti-EGFR antibodies (AT) did not significant improve overall survival (OS) in comparison with chemotherapy in the secondline regimens, in contrast to antiangiogenic drugs. Among this group of MAT, aflibercept provides the best results in a selected group of patients (the highly effective group) and a controlled toxicity profile.https://www.med-sovet.pro/jour/article/view/2742metastatic colorectal cancer (mcrc)targeted therapyaflibercept |
| spellingShingle | L. V. Bolotina A. D. Kaprin Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices Медицинский совет metastatic colorectal cancer (mcrc) targeted therapy aflibercept |
| title | Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices |
| title_full | Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices |
| title_fullStr | Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices |
| title_full_unstemmed | Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices |
| title_short | Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices |
| title_sort | second line targeted therapy for metastatic colorectal cancer possibilities for choices |
| topic | metastatic colorectal cancer (mcrc) targeted therapy aflibercept |
| url | https://www.med-sovet.pro/jour/article/view/2742 |
| work_keys_str_mv | AT lvbolotina secondlinetargetedtherapyformetastaticcolorectalcancerpossibilitiesforchoices AT adkaprin secondlinetargetedtherapyformetastaticcolorectalcancerpossibilitiesforchoices |